Houston-based University of Texas MD Anderson Cancer Center has partnered with P-Cure to develop an upright treatment platform that can deliver either proton or helium ion therapy, enabling physicians to choose the best option for each patient.
MD Anderson will first evaluate P-Cure’s existing upright proton therapy system, according to a Nov. 7 news release from MD Anderson.
The organizations will then conduct preclinical and clinical studies of helium ions, which may target tumors more precisely than protons, the release said.
Under the agreement, MD Anderson is eligible for payments tied to clinical milestones and commercial sales. The cancer center has also disclosed an institutional conflict of interest with P-Cure.
The partnership comes days after MD Anderson announced plans for a $3.4 billion campus expansion. The expansion includes Prism, a radiation therapy and imaging facility with 18 radiation vaults expected to open in 2030.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
